New immunotherapies as a whole "have revolutionized many tumors," he said.
Immunotherapy may also be combined with a different form of therapy than therapy, as shown in the two new studies.
The study showed that progression-free survival averaged 13.8 additional months of life in patients treated with avelumab plus axitinib compared to 7.2 months in sunitinib-treated patients.
The pembrolizumab-axitinib study involved 861 patients with renal cell cancer. Of these, 434 received pembrolizumab intravenously plus axitinib as a treatment and 429 sunitinib.
The study showed that progression-free survival was 15.1 months in the pembrolizumab-axitinib group and 11.1 months in the sunitinib group. Patients receiving the combination therapy had a 47% lower risk of death and a 31% lower risk of progression or death than patients receiving sunitinib.
The percentage of patients still alive 12 months after treatment was 89.9% of the pembrolizumab axitinib group compared to 78.3% in the sunitinib group.
"We measure the effectiveness of anticancer drugs in many different ways – patients who live longer in the first instance – but also other measures, and in all of these measures, this combination was superior to sunitinib," he said. These other measures include response to the treatment and progression of the disease.
"We have learned from other studies, not from kidney cancer, but from other studies, as we begin to combine some of these treatments. The effects can be considerable, and that in itself can be a problem, but the fact is that the addition of the immunotherapeutic prolonged survival longer than standard therapy. "
" Just a matter of a few months, and is this really an improvement given the cost and side effects of immunotherapeutics? But it is also very likely that we have these patients did not pursue it long enough, "he said. "It may therefore happen that some patients will experience a remarkable improvement as a result of this treatment."
The combination treatments studied in both studies are not yet approved by the US Food and Drug Administration for Renal Cell Carcinoma, and the cost of the treatments is unknown.  Nevertheless, the question remains: "Does this change the standard of care? Well, I think, whether this changes the standard of care or not, is discussed among experts," said Lichtenfeld.
"I do not think this study will make an immediate difference overnight, but I suspect that over time it will become a standard treatment for metastatic or recurrent renal cell carcinoma – kidney cancer."
Well, it is noteworthy that this is the case Both of these studies had positive results and demonstrated superiority over sunitinib in terms of progression-free survival and the objective response rate. The pembrolizumab study also showed a benefit in terms of overall survival, "wrote Escudier," and both combinations are expected to become new standards of care and to be included in future guidelines. "
Consider experts in the field not only the new studies, but also the question of how immunotherapies in general influence the treatment approaches 19659025]